Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- Wall Street ends down as oil prices, Treasury yields rise
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Editas Medicine (EDIT) PT Lowered to $10 at Baird
October 22, 2024 1:41 PM EDT(Updated - October 22, 2024 1:41 PM EDT)
Baird analyst Joel Beatty lowered the price target on Editas Medicine (NASDAQ: EDIT) to $10.00 (from $18.00) while maintaining a Outperform rating.
The analyst commented: "Refocusing pipeline on in vivo platform. Editas provided initial data from their in vivo... More
Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024 7:02 AM EDTEditas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic stem and progenitor cell (HSPC) editing and fetal hemoglobin (HbF) induction in humanized mice engrafted with human hematopoietic stem cells and lacking their own hematopoietic cells. The Company observed high levels of editing of the HBG1/2 promoter, leveraging our clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP) formulation for extrahepatic tissue delivery. The Company is also providing business development and financial updates, including... More
